A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor
| Status: | Completed |
|---|---|
| Conditions: | Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 6 - 20 |
| Updated: | 3/29/2019 |
| Start Date: | June 2012 |
| End Date: | August 2017 |
A PHASE I/II STUDY OF SUNITINIB IN YOUNG PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR
Children and young adults with gastrointestinal stromal tumors (GIST) will be treated with
sunitinib. The safety (including pharmacokinetics) and tolerability of sunitinib will be
studied in these patients. In addition, tumor responses and overall survival will be
assessed.
sunitinib. The safety (including pharmacokinetics) and tolerability of sunitinib will be
studied in these patients. In addition, tumor responses and overall survival will be
assessed.
Inclusion Criteria:
- Histological diagnosis of GIST.
- Patients must have demonstrated either disease progression or intolerance to imatinib
mesylate, have non-mutant Stem Cell Factor Receptor gene (KIT) GIST, or cannot obtain
imatinib in their country
- Measurable by Response Evaluation Criterion in Solid Tumors (RECIST) or evaluable
disease.
Exclusion Criteria:
- Current treatment with another investigational agent.
- Prior sunitinib treatment.
- Prior therapy with known risk for cardiovascular complications.
We found this trial at
4
sites
Los Angeles, California 90027
Click here to add this to my saved trials
Click here to add this to my saved trials
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
Click here to add this to my saved trials